Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to measure the concentration of formaldehyde in the urine of women with recurrent urinary tract infections on Hiprex; and then, assuming its urinary presence is confirmed at the proper acid urinary pH, evaluate if such a therapy has favorable effects in decreasing the rate of recurrent urinary tract infections over time.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Methenamine hippurate

Criteria

Inclusion Criteria:

1. Female

2. Age 50 - 85

3. Have RUTIs (at least 2 UTIs within the past 6 months or 3 within the past year) -

Exclusion Criteria:

1. Being on antibiotics at baseline (i.e. suppressive therapy or antibiotic therapy for urinary or non-urinary infections)

2. Neurogenic bladder condition

3. Using urinary catheters (including Foley catheter, intermittent catheterization, and suprapubic catheter)

4. Uncontrolled diabetes (HbA1c > 9)

5. Chronic renal failure defined as serum creatinine > 1.5 mg/dL

6. History of liver disease

7. Patients from out of town, in whom follow-up will not be possible

8. Pregnancy

9. Allergy to Hiprex

10. Inability to take Hiprex reliably at home, such as having psychosis, dementia, or swallowing disorders

11. Non-English speakers -